Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 1/2012

01-02-2012 | Original Article

Sacral neuromodulation in patients with multiple sclerosis

Authors: Daniele Minardi, Giovanni Muzzonigro

Published in: World Journal of Urology | Issue 1/2012

Login to get access

Abstract

Purpose

We present a case series of patients with multiple sclerosis (MS) and neurogenic lower urinary tract dysfunction treated by sacral neuromodulation (SNM).

Methods

We reviewed charts of 25 patients who were treated for refractory lower urinary tract symptoms; during the SNM testing phase, patient management included evaluation of number of daily voiding, number of episodes of incontinence, residual urine and quality of life score. Patients who experienced greater than 50% improvement in symptoms of frequency and incontinence episodes and/or a greater than 50% decrease in the number of catheterizations and a greater than 50% increase in voided volumes were offered placement of the permanent InterStimTM .

Results

Fifteen patients were implanted with InterStimTM; mean duration of MS was 13.66 years; mean follow-up of patients was 49.4 months. Nine patients were on clean intermittent catheterization, and in all of them, a significant decrease in residual volume with increase in voided volume and number of voiding per day; in 6 patients, the main problem was incontinence, and in them incontinence, episodes decreased and voided volume increased. Sixty-six per cent of patients have a functioning device after a mean follow-up of 61.2 months.

Conclusions

SNM is a good option in the treatment of voiding dysfunction in patients with MS in a medium to long-term follow-up. Urinary retention due to detrusor underactivity is not a good indication for SNM; it should be offered to MS patients with refractory urgency urinary incontinence and MS patients with urinary retention due to detrusor-sphincter dyssynergia (DSD).
Literature
1.
Marinkovic SP, Gillen LM (2010) Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int Urogynecol J Pelvic Floor Dysfunct 21(2):223–228CrossRef
2.
3.
Fowler CJ, van Kerrebroeck PE, Nordenbo A, van Poppel H (1992) Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 55:986–989PubMedCrossRef
4.
Ruud Bosh JLH (1998) Neuromodulation: urodynamic effects of sacral (S3)spinal nerve stimulation in patients with detrusor instability or detrusor hyperreflexia. Behav Brain Res 92:141–150CrossRef
5.
Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB (2001) Urodynamic pattern changes in multiple sclerosis. Urology 57:239–245PubMedCrossRef
6.
Minardi D, Muzzonigro G (2005) Lower urinary tract and bowel disorders and multiple sclerosis: role of sacral neuromodulation. A preliminary report. Neuromodulation 8:176–181PubMedCrossRef
7.
Calabresi PA (2004) Diagnosis and management of multiple sclerosis. Am Fam Physician 70:1935–1944PubMed
8.
Littwiller SE, Frohman E, Zimmern P (1999) Multiple sclerosis and the urologist. J Urol 161:743–757CrossRef
9.
Hennessey A, Robertson NP, Swingler R, Compston DA (1999) Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 246:1027–1032PubMedCrossRef
10.
Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D (2007) Disparities in the management of multiple sclerosis –related bladder symptoms. Neurology 68:1971–1978PubMedCrossRef
11.
Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Vespasiani G, Castellano V (1998) Urological dysfunction and upper tract involvement in multiple sclerosis patients. Neurourol Urodyn 17:89–98PubMedCrossRef
12.
DasGupta R, Fowler CJ (1995) Bladder, bowel and sexual dysfunction in multiple sclerosis. Management strategies. Drugs 63:153–166CrossRef
13.
Burks FN, Diokno AC, Laijness MJ, Ibrahim IA, Peters KM (2008) Sacral neuromodulation reprogramming: is it an office burden. Int Urogynecol J Pelvic Floor Dysfunct 19:1137–1140PubMedCrossRef
14.
Roth TM (2007) Sacral neuromodulation and lower urinary tract dysfunction in cerebral plasy. Int Urogynecol J Pelvic Floor Dysfunct 18:567–569PubMedCrossRef
15.
De Ridder D, Ost D, van der Aa F, Stagnaro M, Beneton C, Gross-Paju K, Eelen P, Limbourg H, Harper M, Segal JC, Fowler CJ, Nordenbo A (2005) Conservative bladder management in advanced multiple sclerosis. Multiple Scler 11:694–699CrossRef
16.
Wagner TH, Patrick DL, Bevendam TG, Bueshing DP (1996) Quality of life of persons with urinary incontinence: development of a new measure. Urology 47:67–70PubMedCrossRef
17.
Schäfer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, van Kerrebroeck P, International Continence Society (2002) Good urodynamic practices: uroflowmetry, filling cystometry and pressure-flow studies. Neurourol Urodyn 21:261–274PubMedCrossRef
18.
Minardi D, Parri G, d’Anzeo G, Fabiani A, El Asmar Z, Muzzonigro G (2008) Perineal ultrasound evaluation of dysfunctional voiding in women with recurrent urinary tract infections. J Urol 179:947–951PubMedCrossRef
19.
Spinelli M, Bertapelle P, Cappellano F, Zanollo A, Carone R, Catanzaro F, Giardiello G, De Seta F (on behalf of the GINS group) (2001) Chronic sacral neuromodulation in patients with lower urinary tract symptoms: results from a national register. J Urol 166:541–545
20.
Spinelli M, Sievert KD (2008) Latest technology and surgical developments in using InterStimTM therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol 54:1287–1296PubMedCrossRef
21.
Wallace PA, Lane FL, Noblett KL (2007) Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Ostr Gynecol 197(1):96.e1–96.e5CrossRef
22.
Chartier-Kastler EJ, Ruud Bosch JLH, Perrigot M, Chancellor MB, Richard F, Denys P (2000) Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 164:1476–1480PubMedCrossRef
23.
Bemelmans BL, Mundy AR, Craggs MD (1999) Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction. Eur Urol 36:81–91PubMedCrossRef
24.
Bosch JLHR, Groen J (2000) Sacral neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of prospective longitudinal study. J Urol 163:1849–1854CrossRef
Metadata
Title
Sacral neuromodulation in patients with multiple sclerosis
Authors
Daniele Minardi
Giovanni Muzzonigro
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
World Journal of Urology / Issue 1/2012
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-011-0669-0

Other articles of this Issue 1/2012

World Journal of Urology 1/2012 Go to the issue

Editorial

Editorial

Original Article

Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy

Topic paper

Urologic complications of genitourinary schistosomiasis

Original Article

Childhood dysfunctional voiding is differentially associated with urinary incontinence subtypes in women

Review

Outcomes assessment in men undergoing open retropubic radical prostatectomy, laparoscopic radical prostatectomy, and robotic-assisted radical prostatectomy

Topic Paper

Advances in non-surgical treatments for urinary tract infections in children